Amid crowded migraine market, Lundbeck goes its own way

The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting CGRP for many sufferers, but Lundbeck thinks there is still room for new approaches.

The Danish drugmaker has started a phase 2 trial of a drug with a new mechanism of action, codenamed Lu AG09222, that could potentially be used as an alternative to or alongside CGRP drugs in patients who still get breakthrough headaches despite treatment.